{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:25:50Z","timestamp":1780633550146,"version":"3.54.1"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00451","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T04:29:14Z","timestamp":1585110554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Vinzeigh","family":"Leukes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Walzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelita","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"B1","unstructured":"Global Tuberculosis Report 2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"637813","DOI":"10.1155\/2016\/6378137","article-title":"Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr Res Treat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/bib\/bbr005","article-title":"Literature mining, ontologies and information visualization for drug repurposing","volume":"12","author":"Andronis","year":"2011","journal-title":"Brief Bioinform"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2019.1637280","article-title":"Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis","volume":"11","author":"Rani","year":"2019","journal-title":"J Biomol Struct Dyn."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/cid\/civ631","article-title":"Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the pasteur-bechamp debates: table 1","volume":"61","author":"Zumla","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.2174\/1381612822666160128150636","article-title":"Opportunities and challenges for host-directed therapies in tuberculosis","volume":"22","author":"Sachan","year":"2016","journal-title":"Curr Pharm Des"},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fmed.2017.00171","article-title":"Host-directed therapeutic strategies for tuberculosis","volume":"4","author":"Kolloli","year":"2017","journal-title":"Front Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis","volume":"13","author":"Young","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S4385","article-title":"Inflammatory mechanisms in the lung","volume":"2","author":"Moldoveanu","year":"2008","journal-title":"J Inflamm Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature08123","article-title":"Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase","volume":"460","author":"Agarwal","year":"2009","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrmicro1538","article-title":"Who puts the tubercle in tuberculosis?","volume":"5","author":"Russell","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mrd.22586","article-title":"Role of forward-motility-stimulating factor as an extracellular activator of soluble adenylyl cyclase","volume":"82","author":"Dey","year":"2015","journal-title":"Mol Reprod Dev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.3813","article-title":"A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis","volume":"21","author":"Dey","year":"2015","journal-title":"Nat Med"},{"key":"B14","unstructured":"Advances in targeting cyclic nucleotide phosphodiesterases290314\n            MauriceDH\n            KeH\n            AhmadF\n            WangY\n            ChungJ\n            ManganielloVC\n          10.1038\/nrd422824687066Nat Rev Drug Discov132014"},{"key":"B15","unstructured":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use488520\n            BenderAT\n            BeavoJA\n          10.1124\/pr.58.3.516968949Pharmacol Rev582006"},{"key":"B16","unstructured":"Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice114858\n            SzczypkaM\n            Obminska-MrukowiczB\n          10.1016\/S1734-1140(10)70377-721273672Pharmacol Rep622010"},{"key":"B17","unstructured":"Adjuvant host-directed therapy with types 35 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment5129\n            MaigaM\n            AmmermanNC\n            MaigaMC\n            TounkaraA\n            SiddiquiS\n            PolisM\n          10.1093\/infdis\/jit187J Infect Dis.2082013"},{"key":"B18","unstructured":"Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungse1002262\n            SubbianS\n            TsenovaL\n            O'BrienP\n            YangG\n            KooMS\n            PeixotoB\n          10.1371\/journal.ppat.100226221949656PLoS Pathog72011"},{"key":"B19","unstructured":"Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis788890\n            MaigaMC\n            AhidjoBA\n            MaigaM\n            BishaiWR\n          10.1128\/AAC.02145-1526438491Antimicrob Agents Chemother.592015"},{"key":"B20","unstructured":"Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro95863\n            JeremyJY\n            BallardSA\n            NaylorAM\n            MillerMA\n            AngeliniGD\n          10.1046\/j.1464-410X.1997.00206.x9202566Br J Urol.791997"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM200011023431814","article-title":"Sildenafil in primary pulmonary hypertension","volume":"88","author":"Prasad","year":"2000","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Kaplan","year":"2007","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrurol.2014.53","article-title":"Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS","volume":"11","author":"Cellek","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00345-009-0484-z","article-title":"Sildenafil citratetamsulosin combination is not superior to monotherapy in treating lower urinary tract symptomserectile dysfunction","volume":"28","author":"Tuncel","year":"2010","journal-title":"World J Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of peyronie's disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/jcbfm.2008.33","article-title":"Magnetic resonance imaging investigation of axonal remodelingangiogenesis after embolic stroke in sildenafil-treated rats","volume":"28","author":"Ding","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.007","article-title":"Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks","volume":"18","author":"Silver","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","article-title":"Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer's disease","volume":"164","author":"Cuadrado-Tejedor","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B29","unstructured":"Phosphodiesterase 5 inhibition improves synaptic function, memory, amyloid-beta load in an Alzheimer's disease mouse model807586\n            PuzzoD\n            StaniszewskiA\n            DengSX\n            PriviteraL\n            LeznikE\n            LiuS\n          10.1523\/JNEUROSCI.0864-09.200919553447J Neurosci.292009"},{"key":"B30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00213-008-1278-5","article-title":"A placebo-controlled study of sildenafil effects on cognition in schizophrenia","volume":"202","author":"Goff","year":"2009","journal-title":"Psychopharmacology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","article-title":"Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques","volume":"196","author":"Rutten","year":"2008","journal-title":"Psychopharmacology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.tox.2008.12.017","article-title":"Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity","volume":"257","author":"Lee","year":"2009","journal-title":"Toxicology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bjp.0707605","article-title":"Role of the NO\/cGMP\/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats","volume":"153","author":"Medeiros","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B34","unstructured":"Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO\/cGMP-dependent mechanism234656\n            KatoN\n            MashitaY\n            KatoS\n            MitsufujiS\n            YoshikawaT\n            TakeuchiK\n          10.1007\/s10620-008-0646-719101800Dig Dis Sci.542009"},{"key":"B35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1191\/0961203303lu257cr","article-title":"Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome","volume":"12","author":"Gertner","year":"2003","journal-title":"Lupus"},{"key":"B36","first-page":"2440","article-title":"Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil","volume":"32","author":"Colglazier","year":"2005","journal-title":"J Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"392542","DOI":"10.1155\/2011\/392542","article-title":"PDE-5 inhibitors in scleroderma raynaud phenomenon and digital ulcers: current status of clinical trials","volume":"2011","author":"Impens","year":"2011","journal-title":"Int J Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/ard.2009.116475","article-title":"Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study","volume":"69","author":"Brueckner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/BOR.0000000000000172","article-title":"Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014","volume":"27","author":"Young","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.transproceed.2007.08.077","article-title":"Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure","volume":"39","author":"Maruszewski","year":"2007","journal-title":"Transplant Proc"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.transproceed.2008.05.055","article-title":"Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients","volume":"40","author":"De Santo","year":"2008","journal-title":"Transplant Proc."},{"key":"B42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/lt.21533","article-title":"Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension","volume":"15","author":"Gough","year":"2009","journal-title":"Liver Transplant"},{"key":"B43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.healun.2011.11.009","article-title":"A new preservation solution for lung transplantation: evaluation in a porcine transplantation model","volume":"31","author":"Pizanis","year":"2012","journal-title":"J Heart Lung Transplant."},{"key":"B44","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00266-008-9166-2","article-title":"Evaluation of the effect of sildenafil and vascular endothelium growth factor combination treatment on skin flap survival in rats","volume":"32","author":"Tsai","year":"2008","journal-title":"Aesthetic Plast Surg"},{"key":"B45","unstructured":"Phosphodiesterase inhibitors in female sexual dysfunction3937\n            MayerM\n            StiefCG\n            TrussMC\n            UckertS\n          10.1007\/s00345-005-0015-516247643World J Urol.232005"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.fertnstert.2007.08.043","article-title":"Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage","volume":"90","author":"Jerzak","year":"2008","journal-title":"Fertil Steril"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1515\/CCLM.2009.311","article-title":"Biochemical role of intravaginal sildenafil citrate as a novel antiabortive agent in unexplained recurrent spontaneous miscarriage: first clinical study of four case reports from Egypt","volume":"47","author":"El-Far","year":"2009","journal-title":"Clin Chem Lab Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/humrep\/15.4.806","article-title":"Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flowendometrial development in patients undergoing IVF","volume":"15","author":"Sher","year":"2000","journal-title":"Hum Reprod Oxf Engl"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0015-0282(02)03375-7","article-title":"Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development","volume":"78","author":"Sher","year":"2002","journal-title":"Fertil Steril"},{"key":"B50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11906-011-0204-0","article-title":"Mechanisms and potential therapies for preeclampsia","volume":"13","author":"George","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1742-1241.2006.01087.x","article-title":"PDE5 inhibitors in diabetic peripheral neuropathy","volume":"60","author":"Hackett","year":"2006","journal-title":"Int J Clin Pract"},{"key":"B52","unstructured":"Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice399410\n            WangL\n            ChoppM\n            SzaladA\n            LiuZ\n            BolzM\n            AlvarezFM\n          10.1016\/j.neuroscience.2011.07.03921820491Neuroscience1932011"},{"key":"B53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000080104","article-title":"Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy","volume":"72","author":"Patil","year":"2004","journal-title":"Pharmacology"},{"key":"B54","unstructured":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function2691702\n            SerafiniP\n            MeckelK\n            KelsoM\n            NoonanK\n            CalifanoJ\n            KochW\n          10.1084\/jem.2006110417101732J Exp Med.2032006"},{"key":"B55","unstructured":"Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse modele30749\n            MaigaM\n            AgarwalN\n            AmmermanNC\n            GuptaR\n            GuoH\n            MaigaMC\n          10.1371\/journal.pone.003074922319585PLoS ONE72012"},{"key":"B56","unstructured":"Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction4752\n            BoolellM\n            AllenMJ\n            BallardSA\n            Gepi-AtteeS\n            MuirheadGJ\n            NaylorAM\n          8858389Int J Impot Res.81996"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13C","DOI":"10.1016\/S0002-9149(99)00043-0","article-title":"Effects of sildenafil citrate on human hemodynamics","volume":"83","author":"Jackson","year":"1999","journal-title":"Am J Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1046\/j.0306-5251.2001.00027.x","article-title":"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality","volume":"53","author":"Nichols","year":"2002","journal-title":"Br J Clin Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2125.2001.00318.x","article-title":"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil","volume":"51","author":"Hyland","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1124\/dmd.117.076034","article-title":"Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase enzymes","volume":"45","author":"Cao","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12900-018-0085-4","article-title":"Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function","volume":"18","author":"Dash","year":"2018","journal-title":"BMC Struct Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1365-2125.2000.00245.x","article-title":"Pharmacokinetic interactions between sildenafil and saquinavir\/ritonavir","volume":"50","author":"Muirhead","year":"2000","journal-title":"Br J Clin Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J Immunol Baltim Md"},{"key":"B65","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1164\/rccm.201302-0249OC","article-title":"Increased frequency of myeloid-derived suppressor cells during active tuberculosisafter recent Mycobacterium tuberculosis infection suppresses T-Cell function","volume":"188","author":"du Plessis","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e80669","DOI":"10.1371\/journal.pone.0080669","article-title":"Gr1intCD11b+ myeloid-derived suppressor cells in Mycobacterium tuberculosis infection","volume":"8","author":"Obreg\u00f3n-Henao","year":"2013","journal-title":"PLoS ONE"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.4049\/jimmunol.1301365","article-title":"Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice","volume":"192","author":"Tsiganov","year":"2014","journal-title":"J Immunol Baltim Md"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e0123772","DOI":"10.1371\/journal.pone.0123772","article-title":"Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level","volume":"10","author":"Daker","year":"2015","journal-title":"PLoS ONE"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1164\/rccm.201405-0828OC","article-title":"Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis","volume":"190","author":"Knaul","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12307-012-0126-7","article-title":"Tumor microenvironment and myeloid-derived suppressor cells","volume":"6","author":"Umansky","year":"2013","journal-title":"Cancer Microenviron"},{"key":"B71","doi-asserted-by":"publisher","first-page":"17111","DOI":"10.1073\/pnas.1108121108","article-title":"Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model","volume":"108","author":"Meyer","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B72","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B73","unstructured":"Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model10414\n            SubbianS\n            TsenovaL\n            HollowayJ\n            PeixotoB\n            O'BrienP\n            DartoisV\n          10.1016\/j.ebiom.2016.01.01526981575EBioMedicine42016"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T04:29:20Z","timestamp":1585110560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":73,"alternative-id":["10.3389\/fimmu.2020.00451"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00451","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"article-number":"451"}}